Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Phase:
PHASE2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute